Marquet P - Search Results

1

Phenotyping of Uracil and 5-Fluorouracil Metabolism Using LC-MS/MS for Prevention of Toxicity and Dose Adjustment of Fluoropyrimidines.

Tafzi N, Woillard JB, Fleytoux A, Picard N, Marquet P. Tafzi N, et al. Among authors: marquet p. Ther Drug Monit. 2020 Aug;42(4):540-547. doi: 10.1097/FTD.0000000000000768. Ther Drug Monit. 2020. PMID: 32384537

2

Simultaneous determination of lidocaine and bupivacaine in human plasma: application to pharmacokinetics.

Lotfi H, Debord J, Dreyfuss MF, Marquet P, Ben Rhaiem M, Feiss P, Lachâtre G. Lotfi H, et al. Among authors: marquet p. Ther Drug Monit. 1997 Apr;19(2):160-4. doi: 10.1097/00007691-199704000-00007. Ther Drug Monit. 1997. PMID: 9108643

3

Is LC-MS suitable for a comprehensive screening of drugs and poisons in clinical toxicology?

Marquet P. Marquet P. Ther Drug Monit. 2002 Feb;24(1):125-33. doi: 10.1097/00007691-200202000-00020. Ther Drug Monit. 2002. PMID: 11805733 Review.

4

Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology.

Marquet P. Marquet P. Ther Drug Monit. 2002 Apr;24(2):255-76. doi: 10.1097/00007691-200204000-00008. Ther Drug Monit. 2002. PMID: 11897972 Review.

5

Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis.

Rousseau A, Monchaud C, Debord J, Vervier I, Estenne M, Thiry P, Marquet P. Rousseau A, et al. Among authors: marquet p. Ther Drug Monit. 2003 Feb;25(1):28-35. doi: 10.1097/00007691-200302000-00004. Ther Drug Monit. 2003. PMID: 12548141

6

Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.

Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, Marquet P. Picard N, et al. Among authors: marquet p. Drug Metab Dispos. 2005 Jan;33(1):139-46. doi: 10.1124/dmd.104.001651. Epub 2004 Oct 6. Drug Metab Dispos. 2005. PMID: 15470161

7

In vitro study of mycophenolic acid glucuronidation.

Picard N, Marquet P. Picard N, et al. Among authors: marquet p. Drug Metab Dispos. 2004 Dec;32(12):1524; author reply 1525. doi: 10.1124/dmd.104.001982. Drug Metab Dispos. 2004. PMID: 15550725 No abstract available.

8

Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5.

Picard N, Cresteil T, Prémaud A, Marquet P. Picard N, et al. Among authors: marquet p. Ther Drug Monit. 2004 Dec;26(6):600-8. doi: 10.1097/00007691-200412000-00004. Ther Drug Monit. 2004. PMID: 15570183

9

Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring.

Prémaud A, Rousseau A, Le Meur Y, Lachâtre G, Marquet P. Prémaud A, et al. Among authors: marquet p. Ther Drug Monit. 2004 Dec;26(6):609-19. doi: 10.1097/00007691-200412000-00005. Ther Drug Monit. 2004. PMID: 15570184

10

In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.

Picard N, Cresteil T, Djebli N, Marquet P. Picard N, et al. Among authors: marquet p. Drug Metab Dispos. 2005 May;33(5):689-95. doi: 10.1124/dmd.105.003681. Epub 2005 Mar 2. Drug Metab Dispos. 2005. PMID: 15743975

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

578 results

Search Page

Filters